Form 4: Boundless Bio Directors Report Changes in Beneficial Ownership Following IPO

Following Boundless Bio's initial public offering, several directors and related entities reported changes in their beneficial ownership of the company's common stock due to the conversion of preferred stock and open market purchases.

Summary

• This Form 4 filing reports changes in beneficial ownership of Boundless Bio, Inc. (BOLD) common stock by several directors and related entities.
• The reported transactions occurred on April 2, 2024, and involve the conversion of preferred stock into common stock and open market purchases of common stock.
• Keith Crandell, Clinton Bybee, Robert Nelsen, and Steven Gillis, all associated with ARCH Venture Partners, are listed as reporting persons.
• The changes in ownership reflect transactions by ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and ARCH Venture Fund X Overage, L.P.
• These entities converted Series A, Series B, and Series C convertible preferred stock into common stock upon the closing of Boundless Bio's IPO.
• Additionally, ARCH Venture Fund IX and ARCH Venture Fund X Overage purchased common stock in the IPO at a price of $16 per share.
• The filing includes both direct and indirect ownership details, with disclaimers of beneficial ownership except to the extent of any pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard procedures following an IPO, with directors and major shareholders adjusting their holdings. The purchases in the IPO indicate confidence in the company's prospects.

Positives

• The conversion of preferred stock to common stock indicates confidence in the company's future as a public entity.
• Purchases of common stock in the IPO by major shareholders demonstrate further investment in the company's prospects.

Industry Context

Form 4 filings are standard practice following significant events like IPOs, providing transparency into the ownership structure of the company and the actions of its insiders. This filing is typical for venture capital firms and directors following an IPO, as they adjust their holdings and ownership structures.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for venture capital firms following an IPO, as they often convert preferred stock to common stock and may purchase additional shares in the offering.
• Similar filings can be observed for directors and major shareholders of companies like Moderna, BioNTech, and other biotech firms after their IPOs or significant stock transactions.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of the company.
• The actions of directors and major shareholders can influence investor confidence.

Key Dates